IP Bridge (IPB) – the company that operates Japan’s sovereign patent fund (SPF) – announced last week that it has signed a drug discovery deal with Kyushu University, indicating that it is aiming beyond straight monetisation activities to fulfil its originally stated objectives of facilitating open innovation and putting Japan’s vast stockpile of dormant intellectual property to work.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is a high quality magazine with in-depth articles about intellectual asset management not found in any other publication. It adds value to our profession!

Katharine Ku
Director of the office of technology licensing
Stanford University


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?